Fujifilm Holdings Corp · TSE:4901
Fujifilm — Q2 FY2024 Earnings Presentation
35 slides from Fujifilm's earnings presentation, Nov 7, 2024
Slide 1: Earnings Presentation: Financial Results for Q2 FY2024
Earnings Presentation Financial Results for Q2 FY2024 November 7, 2024 Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management’s current assumptions and beliefs based on currently available information. Such forward-lo
Slide 2: Agenda
Agenda Consolidated Financial Results for Q2 FY2024 (July to September 2024) Earnings Highlights and Key Topics 1 Teiichi Goto, President, Representative Director & CEO FUJIFILM Holdings Corporation Financial Results and Business Summary by Operating Segment 2 Masayuki Higuchi, Director & Corporate
Slide 3: Q2 FY2024 Earnings Highlights and Key Topics
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Q2 FY2024 Earnings Highlights and Key Topics 01 FUJIFILM Holdings Corporation 3
Slide 4: Earnings Highlights for Q2 FY2024
Earnings Highlights Highlights Key Topics Q2 FY2024 FY2024 Forecast Appendices Earnings Highlights for Q2 FY2024 Consolidated Performance for Q2 FY2024 (July to September) (Exchange rates for Q2: ¥149/US$ +¥4 YoY; ¥164/Euro +¥7 YoY) Record high Revenue Record high Operating income Net income attribu
Slide 5: Earnings Highlights for Q2 FY2024: Full-year Forecast
Earnings Highlights Highlights Key Topics Q2 FY2024 FY2024 Forecast Appendices Earnings Highlights for Q2 FY2024 Full-year Consolidated Forecast for FY2024 (Exchange rates for full year: ¥149/US$; ¥163/Euro) Record high Revenue Record high Operating income Net income attributable to FUJIFILM Holding
Slide 6: Key Topics for Q2 FY2024 1/3: Bio CDMO
Earnings Highlights Highlights Key Topics Q2 FY2024 FY2024 Forecast Appendices Key Topics for Q2 FY2024 1/3 Bio CDMO New large-scale facility at the Denmark site (1st phase investment) has launched operations from the first week of November Each of new facilities is being developed based on the trac
Slide 7: Key Topics for Q2 FY2024 2/3: Semiconductor Materials
Earnings Highlights Highlights Key Topics Q2 FY2024 FY2024 Forecast Appendices Key Topics for Q2 FY2024 2/3 Semiconductor Materials Will invest a total of over ¥20 billion in strengthening facilities for development, production and quality evaluation of advanced semiconductor materials at our develo
Slide 8: Key Topics for Q2 FY2024 3/3: Semiconductor Materials
Earnings Highlights Highlights Key Topics Q2 FY2024 FY2024 Forecast Appendices Key Topics for Q2 FY2024 3/3 Semiconductor Materials Contribute to further miniaturization of semiconductors by providing negative-tone EUV resist and EUV developer compatible with the NTI process*1, our proprietary negat
Slide 9: Q2 FY2024 Financial Results and Business Summary by Operating Segment
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Q2 FY2024 Financial Results and Business Summary by Operating Segment 02 * From the Q2 FY2024 earnings, the amounts shown for each item in this document have been rounded to the nearest ¥100 million. As a result, there may be some discrepancie
Slide 10: Financial Results for FY2024 Q2
Earnings Highlights Q2 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Financial Results for FY2024 Q2 (Billions of yen) Q2 H1 Impact of Constant- Impact of Constant- FY2023 FY2024 Change FY2023 FY2024 Change exchange rate currency basis exchange rate currency basis 727.7 Record high
Slide 11: Consolidated Revenue and Operating Income by Operating Segment
Earnings Highlights Q2 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Financial Results for Q2 FY2024 Consolidated Revenue and Operating Income by Operating Segment (Billions of yen) Q2 H1 Revenue FY2023 FY2024 Change FY2023 FY2024 Change Constant-currency basis Constant-currency ba
Slide 12: Business Summary: Healthcare
Earnings Highlights Q2 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Q2 FY2024 (July to September 2024) Business Summary: Healthcare YoY Change Revenue increased in the Medical Systems and the LS Solutions. Operating income decreased mainly due to Revenue Operating income expenses
Slide 13: Business Summary: Electronics
Earnings Highlights Q2 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Q2 FY2024 (July to September 2024) Business Summary: Electronics YoY Change Revenue increased due to a recovery in the semiconductor materials market and sales contribution from the Revenue Operating income acquir
Slide 14: Business Summary: Business Innovation
Earnings Highlights Q2 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Q2 FY2024 (July to September 2024) Business Summary: Business Innovation YoY Change Revenue declined mainly due to inventory adjustments by major OEM customer for multifunction devices (MFPs) in the Revenue Operat
Slide 15: Business Summary: Imaging
Earnings Highlights Q2 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Q2 FY2024 (July to September 2024) Business Summary: Imaging YoY Change Revenue Operating income Revenue and profits soared due to solid sales of instant photo systems and digital cameras. ↑+11.0％ ↑+29.2％ (Billion
Slide 16: Consolidated Balance Sheets
Earnings Highlights Q2 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices Q2 FY2024 Consolidated Balance Sheets (Billions of yen) Change from Change from Mar. 2023 Mar. 2024 Sep. 2024 Mar. 2023 Mar. 2024 Sep. 2024 Mar. 2024 Mar. 2024 Cash and cash equivalents 268.6 179.7 187.1 7.4 Short
Slide 17: Consolidated Cash Flow
Earnings Highlights Q2 FY2024 Company-wide By Segment BS CF FY2024 Forecast Appendices H1 FY2024 (April to September 2024) Consolidated Cash Flow Cash in Cash out (Billions of yen) Adjusted free cash flow excluding business acquisitions FY2022 FY2023 FY2024 H1 H1 H1 Net income 96.6 112.7 110.8 00.0(
Slide 18: Financial Forecast for FY2024
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Financial Forecast for FY2024 03 * From the Q2 FY2024 earnings, the amounts shown for each item in this document have been rounded to the nearest ¥100 million. As a result, there may be some discrepancies from figures published in the past, an
Slide 19: Full-year Consolidated Forecast for FY2024
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Full-year Consolidated Forecast for FY2024 (Billions of yen) FY2024 FY2024 FY2023 Change from Change from Previous forecast Revised forecast Actual FY2023 previous forecast (as of Aug. 7, 2024) (as of Nov. 7, 2024) Revenue 2,960.9 3,150.0 Reco
Slide 20: Financial Forecast by Operating Segment
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Financial Forecast by Operating Segment (Billions of yen) FY2024 FY2024 FY2023 Revenue Previous forecast Revised forecast Change from previous forecast Constant-currency basis Actual (as of Aug. 7, 2024) (as of Nov. 7, 2024) Healthcare 975.1 1
Slide 21: Appendices: Financial Results for Q2 FY2024
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Appendices: Financial Results for Q2 FY2024 04 * From the Q2 FY2024 earnings, the amounts shown for each item in this document have been rounded to the nearest ¥100 million. As a result, there may be some discrepancies from figures published i
Slide 22: Q2 | H1 Earnings
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Q2 ❘ H1 Earnings (Billions of yen) Q2 H1 Revenue FY2024 FY2024 FY2023 Change Constant-currency basis FY2023 Change Constant-currency basis Healthcare 241.4 242.9 1.5 +0.6% (3.6) (1.5%) 448.2 472.0 23.8 +5.3% 0.8 +0.2% Medical Systems 164.6 166
Slide 23: Quarterly Earnings
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Quarterly Earnings (Billions of yen) FY2023 FY2024 Revenue Q1 Q2 Q3 Q4 Q1 Q2 Healthcare 206.8 241.4 242.5 284.4 229.2 242.9 Medical Systems 140.1 164.6 164.7 190.2 157.7 166.9 Bio CDMO 40.9 50.5 50.3 61.8 47.1 48.1 LS Solutions 25.8 26.4 27.5
Slide 24: Operating Income Analysis (Q2 FY2024 vs Q2 FY2023)
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Operating Income Analysis (Q2 FY2024 vs Q2 FY2023) (Billions of yen) Q2 （b-a) (a) (b) FY2023 FY2024 Operation Raw Material Operating Change FX One-time FY2023 FY2024 Detail Actual Actual and others price Q2 Q2 Segment cost Healthcare 31.5 18.8
Slide 25: Full-year Forecast for FY2024: Revenue by business
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Full-year Forecast for FY2024 Revenue by business (Billions of yen) FY2023 FY2024 FY2024 Change from Change from Actual Previous forecast Revised forecast previous year previous forecast (as of Aug 7, 2024) (as of Nov 7, 2024) Healthcare 975.1
Slide 26: Operating Income Analysis (Full-year forecast vs previous forecast)
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Operating Income Analysis (Full-year forecast vs previous forecast) (Billions of yen) Previous Revised (a) (b) forecast forecast Operation Raw Material （b-a) Operating Change FX Previous Revised Detail (Aug 7,2024) (Nov 7,2024) and others pric
Slide 27: Bio CDMO Profitability
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Bio CDMO Profitability (Q2 YoY; FY2024 full-year forecast vs FY2023) Profitability (EBITDA margin) in Q2, excluding one-time costs, was in line with a year ago. Small to medium- scale facilities are expected to move into the black for the full
Slide 28: Consolidated Revenue by Geographical Area
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Consolidated Revenue by Geographical Area (Billions of yen) FY2023 Q2 FY2024 Q2 Change Ratio (%) Ratio (%) Japan 36.1% 501.1 33.3% 504.8 3.7 +0.7% The Americas 22.0% 305.2 20.4% 309.3 4.1 +1.4% Europe 14.3% 198.0 16.7% 253.6 55.6 +28.1% China
Slide 29: Capital Expenditure and Depreciation & Amortization
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Capital Expenditure and Depreciation & Amortization Capital Expenditure and Depreciation & Amortization (Billions of yen) (Billions of yen) 6,000 600.0 Q2 H1 Full Year FY2024 510.0 FY2023 FY2024 FY2023 FY2024 FY2023 Forecast Healthcare 83.6 13
Slide 30: R&D Expenses and SG&A Expenses
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices R&D Expenses and SG&A Expenses (Billions of yen) R&D Expenses｜SG&A Expenses Ratio to revenue 900.0 9,000 40.0% 752.5 (Billions of yen) 710.7 Q2 H1 Full Year 30.0% FY2024 600.0 6,000 FY2023 FY2024 FY2023 FY2024 FY2023 Forecast 25.5% 24.8% Healt
Slide 31: Market Trend and Number of Employees
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices Market Trend and Number of Employees ▐ Exchange rates (average) / Raw material prices (average) FY2023 FY2024 Unit Q1 Q2 Q3 Q4 Full Year Q1 Q2 H1 H2 Full Year US$ ￥/US$ 138 145 148 149 145 156 149 152 145 149 € ￥/€ 150 157 159 161 157 168 164
Slide 32: References
Earnings Highlights Q2 FY2024 FY2024 Forecast Appendices References ▍ FUJIFILM Holdings - Investor Relations https://ir.fujifilm.com/en/investors.html ▍ FUJIFILM Holdings Integrated Report 2024 https://ir.fujifilm.com/en/investors/ir-materials/integrated-report.html ▍ IR Materials https://ir.fujifil
Slide 33: Release of Integrated Report 2024
Release of Integrated Report 2024 Further developed our existing editorial policy of “value creation story centered on innovation”, and produced content with a focus on “how we can make an impact on society” Detailed roadmap for realizing our Group Purpose Key contents Initiatives to realize our G
Slide 34: FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation
Slide 35: FUJIFILM Value from Innovation
FUJIFILM Value from Innovation